Takeda’s TAK-921 improves overall survival in Phase 3 gastric cancer trial

By Public Technologies
  • Takeda’s arcotatug tavatecan improved survival versus physician-selected treatments in Phase 3 G-HOPE-001 involving previously treated CLDN18.2-positive advanced gastric cancer.
  • The drug also delayed disease progression, meeting both primary endpoints; its safety profile was generally manageable.
  • Results were presented at the 2026 European Society for Medical Oncology Congress.
  • The findings will support a planned regulatory filing in Japan; Innovent’s application in China has received priority review.
  • Planned global Phase 3 trials will evaluate the drug in gastric and pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230730BIZWIRE_USPR_____20261021_BW967745) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk